Pretransplant serum CXCL9 and CXCL10 levels fail to predict acute rejection in kidney transplant recipients receiving induction therapy

Transplantation. 2011 Apr 27;91(8):e59-61. doi: 10.1097/TP.0b013e318210de6b.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Basiliximab
  • Biomarkers / blood
  • Chemokine CXCL10 / blood*
  • Chemokine CXCL9 / blood*
  • Graft Rejection / blood
  • Graft Rejection / immunology*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation / adverse effects*
  • Preoperative Period
  • Recombinant Fusion Proteins / therapeutic use*
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Biomarkers
  • CXCL10 protein, human
  • CXCL9 protein, human
  • Chemokine CXCL10
  • Chemokine CXCL9
  • Immunosuppressive Agents
  • Recombinant Fusion Proteins
  • Alemtuzumab
  • Basiliximab